Dirk Pleimes

Dirk Pleimes

Auto-generated profile, based on publicly available information

Dirk Pleimes

Myelo Therapeutics GmbH

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
AAAlberto Ascherio
Alberto Ascherio
KMKassandra L. Munger
Kassandra L. Munger
RWRick White
Rick White
KKKarl Köchert
Karl Köchert
KSKelly Claire Simon
Kelly Claire Simon
CPChristoph Pohl
Christoph Pohl
Multiple sclerosis (MS) is a common cause of neurological disability in young adults.1 Most patients experience bouts of inflammatory demyelination (relapsing-remitting MS) followed years later by treatment-resistant disease progression and brain atrophy.2 A higher MS risk in individuals with low vitamin D intake3 or low circulating 25-hydroxyvitamin D (25[OH]D),4-7 as well as an inverse correlation between vitamin D status and MS activity, have been reported8-11 and suggest that vitamin D is related to the disease process that leads to and perpetuates MS. However, previous clinical studies were conducted among patients with variable disease duration and could not determine whether low vitamin D is a consequence of MS activity12 or whether vitamin D levels early in the disease course contribute to predict long-term progression and disability. Because the prevalence of vitamin D insufficiency (25[OH]D<50 nmol/L [20 ng/mL]) is high,13 supplementation could potentially benefit a large proportion of patients with MS.

6 September 2016 in Neurology
Verified
Journal Article
Open access
PDF file
LKLudwig Kappos
Ludwig Kappos
GEGilles Edan
Gilles Edan
MFMark S. Freedman
Mark S. Freedman
XMXavier Montalban
Xavier Montalban
HHHans-Peter Hartung
Hans-Peter Hartung
EWEva-Maria Wicklein
Eva-Maria Wicklein
Objective: To assess outcomes for patients treated with interferon beta-1b immediately after clinically isolated syndrome (CIS) or after a short delay. Methods: Participants in BENEFIT (Betaferon/Betaseron in Newly Emerging MS for Initial Treatment) were randomly assigned to receive interferon beta-1b (early treatment) or placebo (delayed treatment). After conversion to clinically definite multiple sclerosis (CDMS) or 2 years, patients on placebo could switch to interferon beta-1b or another treatment. Eleven years after randomization, patients were reassessed. Results: Two hundred seventy-eight (59.4%) of the original 468 patients (71.3% of those eligible at participating sites) were enrolled (early: 167 [57.2%]; delayed: 111 [63.1%]). After 11 years, risk of CDMS remained lower in the early-treatment arm compared with the delayed-treatment arm (p = 0.0012), with longer time to first relapse (median [Q1, Q3] days: 1,888 [540, not reached] vs 931 [253, 3,296]; p = 0.0005) and lower overall annualized relapse rate (0.21 vs 0.26; p = 0.0018). Only 25 patients (5.9%, overall; early, 4.5%; delayed, 8.3%) converted to secondary progressive multiple sclerosis. Expanded Disability Status Scale scores remained low and stable, with no difference between treatment arms (median [Q1, Q3]: 2.0 [1.0, 3.0]). The early-treatment group had better Paced Auditory Serial Addition Task–3 total scores (p = 0.0070). Employment rates remained high, and health resource utilization tended to be low in both groups. MRI metrics did not differ between groups. Conclusions: Although the delay in treatment was relatively short, several clinical outcomes favored earlier treatment. Along with low rates of disability and disease progression in both groups, this supports the value of treatment at CIS. ClinicalTrials.gov identifier: NCT01795872. Classification of evidence: This study provides Class IV evidence that early compared to delayed treatment prolongs time to CDMS in CIS after 11 years.

1 November 2013 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
GEG. Edan
G. Edan
LKLudwig Kappos
Ludwig Kappos
XMXavier Montalban
Xavier Montalban
CPC. H. Polman
C. H. Polman
MFM. S. Freedman
M. S. Freedman
FGfor the BENEFIT Study Group
for the BENEFIT Study Group
Objective To examine the long-term impact of early treatment initiation of interferon beta-1b (IFNB1b, Betaferon/Betaseron) in patients with a first event suggestive of multiple sclerosis (MS). Methods In the original placebo-controlled phase of BENEFIT, patients were randomised to IFNB1b 250 μg or placebo subcutaneously every other day. After 2 years or diagnosis of clinically definite MS (CDMS), all patients were offered open-label IFNB1b treatment for a maximum duration of 5 years. Thereafter, patients were enrolled in an observational extension study for up to 8.7 years. Results Of the initial 468 patients, 284 (60.7%; IFNB1b: 178 (61.0% of the original arm), placebo: 106 (60.2% of original arm)) were enrolled in the extension study. 94.2% of patients were receiving IFNB1b. Patients originally randomised to IFNB1b had a reduced risk of developing CDMS by 32.2% over the 8-year observation period (HR 0.678; 95% CI 0.525 to 0.875; p=0.0030), a longer median time to CDMS by 1345 days (95% CI 389 to 2301), and a lower annualised relapse rate (0.196 (95% CI 0.176 to 0.218) versus 0.255 (95% CI 0.226 to 0.287), p=0.0012), with differences mainly emerging in the first year of the study. Cognitive outcomes remained higher in the early treated patients. EDSS remained low over time with a median of 1.5 in both arms. Conclusions These 8-year results provide further evidence supporting early initiation of treatment with IFNB1b in patients with a first event suggestive of MS.

4 April 2012 in Multiple Sclerosis Journal
Verified
Journal Article
Open access
IPIris-Katharina Penner
Iris-Katharina Penner
BSBrigitte Stemper
Brigitte Stemper
PCPasquale Calabrese
Pasquale Calabrese
MFMark S Freedman
Mark S Freedman
CPChris H Polman
Chris H Polman
RSRupert Sandbrink
Rupert Sandbrink
Background: Cognitive dysfunction occurs at the earliest stages of multiple sclerosis (MS), including the stage of clinically isolated syndrome (CIS). Methods: We evaluated the impact of interferon beta-1b (IFNβ-1b) 250 µg on cognitive performance during the CIS stage in the BENEFITstudy. Cognition was assessed by Paced Auditory Serial Addition Test-3” (PASAT-3”) scores. Results: Improvement in PASAT-3” score from baseline to year two was greater for IFNβ-1b treatment than placebo in patients not reaching clinically definite MS (CDMS) by year two. The treatment effect was maintained at year five and was statistically significant. Conclusions: To conclude, early IFNβ-1b treatment had a sustained positive effect on PASAT-3” score over the 5-year BENEFIT study.

22 August 2014 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
KMKassandra L. Munger
Kassandra L. Munger
KKKarl Köchert
Karl Köchert
KSKelly C. Simon
Kelly C. Simon
LKLudwig Kappos
Ludwig Kappos
CPChris H. Polman
Chris H. Polman
CPChristoph Pohl
Christoph Pohl
Objective: Some previous studies suggest modest to strong effects of 25‐hydroxyvitamin D (25(OH)D) on multiple sclerosis (MS) activity. The objective of this study was to explore the mechanistic rationale that may explain potential clinical effects of 25(OH)D.Methods: This study measured serum 25(OH)D levels and global gene expression profiles over a course of up to 2 years in patients starting treatment with interferon beta‐1b (IFNB‐1b) after a clinically isolated syndrome.MSdisease activity was assessed by the number of gadolinium‐enhancing lesions present on repeated magnetic resonance imaging (MRIs).Results: The number of gadolinium‐enhancing lesions was highly significantly associated with 25(OH)D levels. Conducting various systems‐level analyses on the molecular level, multiple lines of evidence indicated that 25(OH)D regulates expression dynamics of a large gene–gene interaction system which primarily regulates immune modulatory processes modulatingMSactivity. The vitamin D response element was significantly enriched in this system, indicating a direct regulation of this gene interaction network through the vitamin D receptor. With increasing 25(OH)D levels, resulting regulation of this system was associated with a decrease inMSactivity. Within the complex network of genes that are regulated by 25(OH)D, well‐described targets ofIFNB‐1b and a regulator of sphingosine‐1‐phosphate bioavailability were found. The 25(OH)D effects onMSactivity were additively enhanced byIFNB‐1b.Interpretation: Here, we provide mechanistic evidence that an unbalanced 25(OH)D gene expression system may affectMSactivity. Our findings support a potential benefit of monitoring and managing vitamin D levels (e.g., through supplementation) in earlyMSpatients treated withIFN‐beta‐1b.

1 May 2014 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
DKD.W. Kaufman
D.W. Kaufman
SRS. Reshef
S. Reshef
HGH.L. Golub
H.L. Golub
MPM. Peucker
M. Peucker
MCM.J. Corwin
M.J. Corwin
GCG. Cutter
G. Cutter